CEL SCI CORP Files 2024 10-K
Ticker: CVM · Form: 10-K · Filed: Jan 13, 2025 · CIK: 725363
Sentiment: neutral
Topics: 10-K, financials, biotech
TL;DR
CEL SCI CORP 2024 10-K filed. $63.8M assets, $47.4M liabilities. Vienna, VA.
AI Summary
CEL SCI CORP filed its 2024 10-K on January 13, 2025, reporting on its fiscal year ending September 30, 2024. The company, previously known as INTERLEUKIN 2 INC, is in the biological products sector. Key financial data for the fiscal year 2024 includes total assets of $63.8 million and total liabilities of $47.4 million. The company's principal business address is in Vienna, VA.
Why It Matters
This filing provides investors with a comprehensive overview of CEL SCI CORP's financial health and operational status for the fiscal year 2024, including assets, liabilities, and business activities.
Risk Assessment
Risk Level: medium — As a biotechnology company, CEL SCI CORP faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- $63.8B — Total Assets (As of September 30, 2024)
- $47.4B — Total Liabilities (As of September 30, 2024)
- 0930 — Fiscal Year End (Indicates the end of the company's annual reporting period)
Key Players & Entities
- CEL SCI CORP (company) — Filer of the 10-K
- INTERLEUKIN 2 INC (company) — Former name of CEL SCI CORP
- 2024-09-30 (date) — End of the reporting fiscal year
- 2025-01-13 (date) — Filing date of the 10-K
- $63,787,104 (dollar_amount) — Total assets for fiscal year 2024
- $47,422,304 (dollar_amount) — Total liabilities for fiscal year 2024
- Vienna, VA (location) — Business address
FAQ
What is the primary business of CEL SCI CORP?
CEL SCI CORP is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
When did CEL SCI CORP file its 2024 10-K?
CEL SCI CORP filed its 2024 10-K on January 13, 2025.
What were CEL SCI CORP's total assets at the end of fiscal year 2024?
CEL SCI CORP reported total assets of $63,787,104 for the fiscal year ending September 30, 2024.
What were CEL SCI CORP's total liabilities at the end of fiscal year 2024?
CEL SCI CORP reported total liabilities of $47,422,304 for the fiscal year ending September 30, 2024.
Where is CEL SCI CORP headquartered?
CEL SCI CORP's business and mailing address is 8229 BOONE BLVD, SUITE 802, VIENNA, VA 22182.
Filing Stats: 4,521 words · 18 min read · ~15 pages · Grade level 13.9 · Accepted 2025-01-13 16:16:33
Key Financial Figures
- $196.45 billion — therapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% durin
- $200 million — CEL-SCI spent many years and more than $200 million developing and validating the manufactu
Filing Documents
- cvm_10k.htm (10-K) — 1527KB
- cvm_ex19.htm (EX-19) — 45KB
- cvm_ex231.htm (EX-23.1) — 2KB
- cvm_ex31.htm (EX-31) — 22KB
- cvm_ex32.htm (EX-32) — 4KB
- cvm_10kimg14.jpg (GRAPHIC) — 46KB
- cvm_10kimg18.jpg (GRAPHIC) — 34KB
- cvm_10kimg17.jpg (GRAPHIC) — 42KB
- cvm_10kimg16.jpg (GRAPHIC) — 29KB
- cvm_10kimg15.jpg (GRAPHIC) — 27KB
- cvm_10kimg10.jpg (GRAPHIC) — 22KB
- cvm_10kimg11.jpg (GRAPHIC) — 19KB
- cvm_10kimg12.jpg (GRAPHIC) — 13KB
- cvm_10kimg13.jpg (GRAPHIC) — 30KB
- 0001654954-25-000288.txt ( ) — 6623KB
- cvm-20240930.xsd (EX-101.SCH) — 54KB
- cvm-20240930_lab.xml (EX-101.LAB) — 349KB
- cvm-20240930_cal.xml (EX-101.CAL) — 49KB
- cvm-20240930_pre.xml (EX-101.PRE) — 288KB
- cvm-20240930_def.xml (EX-101.DEF) — 145KB
- cvm_10k_htm.xml (XML) — 819KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as "anticipates," "believes," "expects," "intends," "future," "could," "estimates," "plans," "would," "should," "potential," "continues" and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to: the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine; our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceedings; the success of our clinical studies for our product candidates; our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards; our expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits and effectiveness of our product candidates; the safety profile and related adverse events of our product candidates; our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals; our plans with respect to collaborations and
BUSINESS
ITEM 1. BUSINESS CEL-SCI's PRODUCT CANDIDATES CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies: 1) Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and 2) L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI's future anticipated regulatory submission for approval. None of CEL-SCI's product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted. MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD Immunotherapy is a large, high growth market. Immunotherapies use the patient's own immune system to fight disease. These "targeted therapies" are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that: The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report b